title: Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.
abstract: BACKGROUND
  The maturation inhibitor bevirimat (BVM) potently inhibits human immunodeficiency virus type 1 (HIV-1) replication by blocking capsid-spacer peptide 1 (CA-SP1) cleavage. Recent clinical trials demonstrated that a significant proportion of HIV-1-infected patients do not respond to BVM. A patient's failure to respond correlated with baseline polymorphisms at SP1 residues 6-8.
  
  
  RESULTS
  In this study, we demonstrate that varying levels of BVM resistance are associated with point mutations at these residues. BVM susceptibility was maintained by SP1-Q6A, -Q6H and -T8A mutations. However, an SP1-V7A mutation conferred high-level BVM resistance, and SP1-V7M and T8Delta mutations conferred intermediate levels of BVM resistance.
  
  
  CONCLUSIONS
  Future exploitation of the CA-SP1 cleavage site as an antiretroviral drug target will need to overcome the baseline variability in the SP1 region of Gag.
authors.affiliation: Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702-1201, USA. catherine.adamson@st-andrews.ac.uk
authors.forename: Catherine S
authors.initials: CS
authors.lastname: Adamson
authors.forename: Michael
authors.initials: M
authors.lastname: Sakalian
authors.forename: Karl
authors.initials: K
authors.lastname: Salzwedel
authors.forename: Eric O
authors.initials: EO
authors.lastname: Freed
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests; D017354:Point Mutation; D011110:Polymorphism, Genetic; D017384:Sequence Deletion; D013386:Succinates / Q000494:pharmacology*; D014315:Triterpenes / Q000494:pharmacology*; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000235:genetics*; D053978:Pentacyclic Triterpenes
chemical_list: D019380:Anti-HIV Agents; D013386:Succinates; D014315:Triterpenes; D054301:gag Gene Products, Human Immunodeficiency Virus; C479935:bevirimat; D053978:Pentacyclic Triterpenes
references.citation: Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81
references.pmid: 17638699
references.citation: J Virol. 1994 Dec;68(12):8017-27
references.pmid: 7966591
references.citation: Expert Opin Ther Targets. 2009 Aug;13(8):895-908
references.pmid: 19534569
references.citation: J Virol. 1998 Apr;72(4):2855-64
references.pmid: 9525605
references.citation: J Virol. 2009 May;83(10):4884-94
references.pmid: 19279107
references.citation: Retrovirology. 2004 Jun 29;1:15
references.pmid: 15225375
references.citation: Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60
references.pmid: 14573704
references.citation: J Nat Prod. 1994 Feb;57(2):243-7
references.pmid: 8176401
references.citation: J Virol. 1998 Apr;72(4):2846-54
references.pmid: 9525604
references.citation: Curr Top Microbiol Immunol. 1996;214:95-131
references.pmid: 8791726
references.citation: J Virol. 1998 May;72(5):4116-26
references.pmid: 9557701
references.citation: Antimicrob Agents Chemother. 2007 Sep;51(9):3063-6
references.pmid: 17576843
references.citation: J Infect. 2007 Apr;54(4):367-74
references.pmid: 16875739
references.citation: AIDS Rev. 2007 Jul-Sep;9(3):162-72
references.pmid: 17982941
references.citation: Trends Mol Med. 2005 Jan;11(1):31-6
references.pmid: 15649820
references.citation: J Virol. 2006 Nov;80(22):10957-71
references.pmid: 16956950
references.citation: Virology. 2006 Dec 5-20;356(1-2):217-24
references.pmid: 16930665
references.citation: Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
references.pmid: 12019106
references.citation: J Virol. 1994 Apr;68(4):2503-12
references.pmid: 8139032
references.citation: Clin Pharmacokinet. 2007;46(7):589-98
references.pmid: 17596104
references.citation: PLoS One. 2007 Nov 28;2(11):e1251
references.pmid: 18043758
references.citation: AIDS. 2007 Apr 23;21(7):871-3
references.pmid: 17415044
references.citation: J Virol. 1986 Aug;59(2):284-91
references.pmid: 3016298
references.citation: Curr Opin Struct Biol. 2008 Apr;18(2):203-17
references.pmid: 18406133
references.citation: AIDS Res Hum Retroviruses. 1989 Dec;5(6):577-91
references.pmid: 2692658
references.citation: J Virol. 1991 Feb;65(2):922-30
references.pmid: 1987379
references.citation: Antimicrob Agents Chemother. 2009 May;53(5):2185-8
references.pmid: 19223634
references.citation: J Virol. 2006 Dec;80(24):12095-101
references.pmid: 17035324
references.citation: J Virol. 1988 Nov;62(11):4393-7
references.pmid: 3050149
references.citation: Proc Natl Acad Sci U S A. 1988 Dec;85(24):9580-4
references.pmid: 2849111
references.citation: J Biol Chem. 2005 Dec 23;280(51):42149-55
references.pmid: 16251182
references.citation: J Virol. 2004 Jan;78(2):922-9
references.pmid: 14694123
references.citation: J Virol. 1988 Nov;62(11):3993-4002
references.pmid: 3262776
references.citation: Antivir Chem Chemother. 2008;19(3):107-13
references.pmid: 19024627